Stockreport

BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push [Yahoo! Finance]

BioMarin Pharmaceutical Inc.  (BMRN) 
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
PDF Under the terms of the agreement, BioMarin will pay cash for all of Amicus' shares for a total consideration of $4.8bn. This deal will set BioMarin back $14.50 per shar [Read more]